Search Patents
  • Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein
    Publication number: 20070190065
    Abstract: Nucleic acid molecules, polypeptides, immunogenic compositions, vaccines, and methods of making and using the nucleotides and encoded polypeptides associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.
    Type: Application
    Filed: December 4, 2006
    Publication date: August 16, 2007
    Inventors: Ralf Altmeyer, Beatrice Nal-Rogier, Cheman Chan, Francois Kien, Yiu Kam, Yu Siu, Kong Tse, Isabelle Staropoli, Jean-Claude Manuguerra
  • ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
    Publication number: 20230105209
    Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
    Type: Application
    Filed: October 3, 2022
    Publication date: April 6, 2023
    Inventors: Kuo-I LIN, Che MA, Chi-Huey WONG, Szu-Wen WANG, Yi-Hsuan CHANG, Xiaorui CHEN, Han-Yi HUANG
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20230338508
    Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
    Type: Application
    Filed: March 10, 2021
    Publication date: October 26, 2023
    Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
  • Antibody specific to spike protein of SARS-CoV-2 and uses thereof
    Patent number: 11866485
    Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: January 9, 2024
    Assignee: ACADEMIA SINICA
    Inventors: Kuo-I Lin, Che Ma, Chi-Huey Wong, Szu-Wen Wang, Yi-Hsuan Chang, Xiaorui Chen, Han-Yi Huang
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20240075129
    Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
    Type: Application
    Filed: October 17, 2023
    Publication date: March 7, 2024
    Applicant: ImmunityBio, Inc.
    Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
  • Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated as a vaccine
    Patent number: 11406702
    Abstract: A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: August 9, 2022
    Inventor: David Gordon Bermudes
  • Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof
    Patent number: 12077572
    Abstract: The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
    Type: Grant
    Filed: September 25, 2022
    Date of Patent: September 3, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, KOREA (CENTER FOR DISEASE CONTROL AND PREVENTION)
    Inventors: Hansaem Lee, Janghoon Choi, Sungsoon Kim, Lingshu Wang, Barney Graham, John R Mascola
  • Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
    Patent number: 10973908
    Abstract: A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 13, 2021
    Inventor: David Gordon Bermudes
  • CLEAVING PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220227842
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Application
    Filed: April 28, 2021
    Publication date: July 21, 2022
    Inventors: Yang Xiang, Yan Tan
  • Quantum Dot Conjugated Virus Spike Protein for Cell-Based Bio-Sensing Systems and Drug Screening
    Publication number: 20220034884
    Abstract: Quantum dots conjugated to SARS-CoV-2 Spike protein receptor binding domain (RBD) interact with gold nanoparticles bound to angiotensin converting enzyme 2 (ACE2) and thus undergo energy transfer. This energy transfer indicates RBD/ACE binding and can be used to assay for inhibitors thereof. Moreover, these labeled quantum dots were found to undergo endocytosis in cells expressing ACE2.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 3, 2022
    Inventors: Eunkeu Oh, Kimihiro Susumu, Mason A. Wolak, Kirill Gorshkov
  • CLEAVING PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220064266
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Application
    Filed: April 28, 2021
    Publication date: March 3, 2022
    Inventors: Yang Xiang, Yan Tan
  • SARS CORONAVIRUS 2 DIAGNOSTIC KIT INCLUDING RECEPTOR AND ANTIBODY BINDING TO SARS CORONAVIRUS 2 SPIKE PROTEIN
    Publication number: 20230160895
    Abstract: Provided are a composition for detecting SARS coronavirus 2, a composition for diagnosing SARS coronavirus 2 infection, a method for detecting SARS coronavirus 2, and a SARS coronavirus 2 infection diagnostic kit, wherein a receptor and an antibody that binds to SARS coronavirus 2 spike protein are used in order to detect SARS coronavirus 2 (SARS-CoV-2) or diagnose SARS coronavirus 2 infection (COVID-19).
    Type: Application
    Filed: June 18, 2021
    Publication date: May 25, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Hong Gi KIM, Jonghwan LEE, Bum Tae KIM
  • BINDING AGENTS TO PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20210403537
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Application
    Filed: September 17, 2020
    Publication date: December 30, 2021
    Inventors: Yang Xiang, Yan Tan
  • RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF
    Publication number: 20240000920
    Abstract: The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.
    Type: Application
    Filed: November 11, 2021
    Publication date: January 4, 2024
    Applicant: Intervet Inc.
    Inventors: Martijn Alexander Langereis, Ad De Groof, Paul Vermeij, Berend Jan Bosch
  • RECOMBINANT SARS-COV-2 SPIKE PROTEIN SUBUNITS, EXPRESSION AND USES THEREOF
    Publication number: 20230312656
    Abstract: The present invention is directed to the expression and secretion recombinant SARS-CoV-2 spike protein subunits. Various subunits have been designed and expressed as secreted products into the culture medium of transformed insect cell lines. The design of subunits is focused on the production of products that provide the ability to induce focused immune responses without inducing immune enhancing responses. The expressed and purified products are suitable as vaccine candidates to protect against disease caused by SARS-CoV-2.
    Type: Application
    Filed: September 1, 2021
    Publication date: October 5, 2023
    Inventors: David E. Clements, James T. Senda, Jaime S. Horton
  • ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220213176
    Abstract: The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 7, 2022
    Inventors: Peixiang Ma, Guang Yang, Richard A. Lerner, Min Qiang, Hou Wang
  • Non-integrating comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein
    Patent number: 11129890
    Abstract: The present invention is directed to recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface (“SARS-CoV-2 S Protein Lentiviral Particles”), and that optionally comprise an additional copy of a polynucleotide encoding the SARS-CoV-2 spike (S) protein in their viral genome, and to methods for the production of such lentiviral particles. The invention particularly pertains to such SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of their lentiviral genome into the chromosomes of infected cells and/or to be incapable of mediating the reverse transcription of their lentiviral genome. The present invention is also directed to “SARS-CoV-2 S Protein Lentiviral Vaccine” pharmaceutical compositions that comprise such SARS-CoV-2 S Protein Lentiviral Particles.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: September 28, 2021
    Assignee: Vigene Biosciences, Inc.
    Inventor: Zairen Sun
  • Cleaving pre-fusion state SARS-CoV-2 spike protein
    Patent number: 11746142
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: September 5, 2023
    Assignee: ABCLONAL SCIENCE, INC.
    Inventors: Yang Xiang, Yan Tan
  • Binding agents to pre-fusion state SARS-CoV-2 spike protein
    Patent number: 11421019
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 23, 2022
    Inventors: Yang Xiang, Yan Tan
  • HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230312689
    Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 5, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, The University of Tokyo
    Inventors: Shuzo MATSUSHITA, Yu KAKU, Takeo KUWATA, Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI
Narrow Results

Filter by US Classification